Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.645 USD | +0.83% | -1.54% | -14.15% |
May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.15% | 13.49M | - | ||
+40.31% | 54.04B | B- | ||
+45.43% | 41.96B | A | ||
-1.63% | 41.92B | B | ||
-7.20% | 28.35B | C | ||
+11.70% | 26.35B | B- | ||
-21.55% | 19B | B | ||
+5.96% | 13B | B+ | ||
+29.12% | 12.28B | C+ | ||
+25.34% | 12.19B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TRAW Stock
- Ratings Traws Pharma, Inc.